NCT00141843View on ClinicalTrials.gov

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions

Hemophilia A

Interventions

GENETIC

ReFacto AF

GENETIC

B-Domain deleted Recombinant Factor VIII

GENETIC

BDDrFVIII

Trial Locations (41)

3000

Leuven

6000

Perth

10249

Berlin

11040

New Hyde Park

14215

Buffalo

17033

Hershey

20122

Milan

22908

Charlottesville

27599

Chapel Hill

28046

Madrid

30322

Atlanta

37232

Nashville

45404

Dayton

46009

Valencia

48143

Münster

48823

East Lansing

52242

Iowa City

63014

St Louis

70112

New Orleans

76031

Rouen

77030

Houston

80045

Aurora

84113

Salt Lake City

85016

Phoenix

92123

San Diego

94275

Le Kremlin-Bicêtre

95817

Sacramento

01605

Worcester

08903-0019

New Brunswick

Unknown

Philadelphia

Groningen

Auckland

Hamilton

Poznan

Wroclaw

Malmo

00029

Helsinki

H-1135

Budapest

95-510

Lodz

00-576

Warsaw

171 76

Stockholm

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00141843 - Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A | Biotech Hunter | Biotech Hunter